Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse

被引:120
|
作者
Nishino, Yasuhiro [1 ]
Webb, Ian G. [1 ]
Davidson, Sean M. [2 ]
Ahmed, Aminul I. [1 ]
Clark, James E. [1 ]
Jacquet, Sebastien [1 ]
Shah, Ajay M. [1 ]
Miura, Tetsuji [3 ]
Yellon, Derek M. [2 ]
Avkiran, Metin [1 ]
Marber, Michael S. [1 ]
机构
[1] Kings Coll London, St Thomas Hosp, Rayne Inst, Dept Cardiol,BHF Ctr, London SE1 7EH, England
[2] UCL Hosp, Hatter Cardiovasc Inst, London, England
[3] Sapporo Med Univ, Sch Med, Dept Internal Med 2, Sapporo, Hokkaido, Japan
基金
英国惠康基金;
关键词
postconditioniong; preconditioning; GSK-3; mPTP;
D O I
10.1161/CIRCRESAHA.107.169953
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The inactivation of glycogen synthase kinase-3 beta (GSK-3 beta) is proposed as the event integrating protective pathways initiated by preconditioning and other interventions. The inactivation of GSK-3 is thought to decrease the probability of opening of the mitochondrial permeability transition pore. The aim of this study was to verify the role of GSK-3 using a targeted mouse line lacking the critical N-terminal serine within GSK-3 beta (Ser9) and the highly homologous GSK-3 beta (Ser21), which when phosphorylated results in kinase inactivation. Postconditioning with 10 cycles of 5 seconds of reperfusion/5 seconds of ischemia and preconditioning with 6 cycles of 4 minutes of ischemia/6 minutes of reperfusion, similarly reduced infarction of the isolated perfused mouse heart in response to 30 minutes of global ischemia and 120 minutes of reperfusion. Preconditioning caused noticeable inactivating phosphorylation of GSK-3. However, both preconditioning and postconditioning still protected hearts of homozygous GSK-3 double knockin mice. Moreover, direct pharmacological inhibition of GSK-3 catalytic activity with structurally diverse inhibitors before or after ischemia failed to recapitulate conditioning protection. Nonetheless, cyclosporin A, a direct mitochondrial permeability transition pore inhibitor, reduced infarction in hearts from both wild-type and homozygous GSK-3 double knockin mice. Furthermore, in adult cardiac myocytes from GSK-3 double knockin mice, insulin exposure was still as effective as cyclosporin A in delaying mitochondrial permeability transition pore opening. Our results, which include a novel genetic approach, suggest that the inhibition of GSK-3 is unlikely to be the key determinant of cardioprotective signaling in either preconditioning or postconditioning in the mouse.
引用
收藏
页码:307 / 314
页数:8
相关论文
共 50 条
  • [41] Glycogen synthase kinase-3β activity in endothelial cells is required for vascular tube formation
    Hirase, T
    Kawashima, S
    Matsui, K
    Inoue, N
    Hirata, K
    CIRCULATION, 2002, 106 (19) : 137 - 137
  • [42] The neuron-specific isoform of glycogen synthase kinase-3β is required for axon growth
    Castano, Zafira
    Gordon-Weeks, Phillip R.
    Kypta, Robert M.
    JOURNAL OF NEUROCHEMISTRY, 2010, 113 (01) : 117 - 130
  • [43] Glycogen synthase kinase-3β is required for SCF-mediated human mast cell
    Radinger, M.
    Kuhen, H.
    Metcalfe, D.
    Lotvall, J.
    Gilfillan, A.
    ALLERGY, 2010, 65 : 7 - 7
  • [44] Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective
    Tong, HY
    Imahashi, K
    Steenbergen, C
    Murphy, E
    CIRCULATION RESEARCH, 2002, 90 (04) : 377 - 379
  • [45] Blind docking of manzamines into glycogen synthase kinase-3β
    Sivaprakasam, P.
    Hamann, M.
    Doerksen, R. J.
    PLANTA MEDICA, 2008, 74 (03) : 335 - 335
  • [46] INHIBITION OF GLYCOGEN-SYNTHASE KINASE-3 BY POLYCATIONS
    HEGAZY, MG
    SCHLENDER, KK
    WILSON, SE
    REIMANN, EM
    FASEB JOURNAL, 1988, 2 (04): : A596 - A596
  • [47] QSAR modeling of the inhibition of Glycogen Synthase Kinase-3
    Katritzky, Alan R.
    Pacureanu, Liliana M.
    Dobchev, Dimitar A.
    Fara, Dan C.
    Duchowicz, Pablo R.
    Karelson, Mati
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (14) : 4987 - 5002
  • [48] Glycogen synthase kinase-3 a negative regulator of hypertrophy
    Haq, SE
    Choukroun, G
    Lee, KH
    Ranu, H
    Vayssier-Taussat, M
    Boecker, W
    Woodgett, J
    Molkentin, JD
    Michael, A
    Force, T
    CIRCULATION, 2000, 102 (18) : 140 - 140
  • [49] Inactivation of glycogen synthase kinase-3β (GSK-3β) enhances skeletal muscle oxidative metabolism
    Theeuwes, W. F.
    Gosker, H. R.
    Langen, R. C. J.
    Verhees, K. J. P.
    Pansters, N. A. M.
    Schols, A. M. W. J.
    Remels, A. H. V.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2017, 1863 (12): : 3075 - 3086
  • [50] Glycogen synthase kinase-3: A potential target for diabetes
    Teli, Divya M.
    Gajjar, Anuradha K.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 92